New research from Oracle Health Services in partnership with Informa Engage/Pharma Intelligence has revealed that more than 60% of drug safety experts are planning to use artificial intelligence (AI) to improve the speed and security of adverse event case processing.
AI digital
“Safety teams are under immense pressure to work quickly and accurately, but their biggest concerns are patient safety and the protection of their data,” explained Andrea Charles, editor, Custom Content, Informa Pharma Intelligence. “They need a robust approach to pharmacovigilance that allows them to work faster while maintaining a high standard of accuracy and security, which is why they are replacing and enhancing their systems with advanced technologies that are fit for the job.”